MOPA — Medical Oncology Prior Authorization - Local Development build (v0.1.1-snapshot-080926) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: Example Regimen Definition: PHD (Pertuzumab + Trastuzumab + Docetaxel)

Raw json | Download

{
  "resourceType" : "PlanDefinition",
  "id" : "RegimenPHD",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/us/codex-mopa/StructureDefinition/anticancer-regimen-plandefinition"
    ]
  },
  "language" : "en",
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n  <table class=\"narrative-table\">\n    <tbody>\n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">Metadata</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">PHD: Pertuzumab + Trastuzumab + Docetaxel — Metastatic HER2+ Breast Cancer</td>\n\n\n</tr>\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Version</th>\n\n\n\n<td class=\"content-container\">0.1.1-snapshot-080926</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Experimental</th>\n\n\n\n<td class=\"content-container\">true</td>\n\n\n</tr>\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Subject Type</th>\n\n\n\n<td class=\"content-container\">\n    Malignant neoplasm of breast\n\n\n</td>\n\n\n</tr>\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Jurisdiction</th>\n\n\n\n<td class=\"content-container\">\n    United States of America\n\n\n</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Steward (Publisher)</th>\n\n\n\n<td class=\"content-container\">HL7 International / Clinical Interoperability Council</td>\n\n\n</tr>\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Steward Contact</th>\n\n\n\n<td class=\"content-container\">HL7 International / Clinical Interoperability Council</td>\n\n\n</tr>\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Description</th>\n\n\n\n<td class=\"content-container\"><div><p>PHD regimen every 21 days for HER2+ metastatic breast cancer. Standard of care per CLEOPATRA trial.</p>\n</div></td>\n\n\n</tr>\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Type</th>\n\n\n\n<td class=\"content-container\">\n    Order Set\n\n\n</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">PlanDefinition Action</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Id</th>\n\n\n\n<td class=\"content-container\">pertuzumab-phd</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">Pertuzumab 840 mg IV (cycle 1), then 420 mg IV q21d</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Timing</th>\n\n\n\n<td class=\"content-container\">Once per 21 days</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">PlanDefinition Action</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Id</th>\n\n\n\n<td class=\"content-container\">trastuzumab-phd</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">Trastuzumab 8 mg/kg IV (cycle 1), then 6 mg/kg IV q21d</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Timing</th>\n\n\n\n<td class=\"content-container\">Once per 21 days</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">PlanDefinition Action</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Id</th>\n\n\n\n<td class=\"content-container\">docetaxel-phd</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">Docetaxel 75 mg/m² IV — Day 1 of each 21-day cycle</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Timing</th>\n\n\n\n<td class=\"content-container\">Once per 21 days</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n  <th colspan=\"2\" scope=\"row\" class=\"row-header\">Generated using version 0.5.4 of the sample-content-ig Liquid templates</th>\n</tr>\n\n    </tbody>\n  </table>\n</div>"
  },
  "url" : "http://hl7.org/fhir/us/codex-mopa/PlanDefinition/RegimenPHD",
  "version" : "0.1.1-snapshot-080926",
  "name" : "RegimenPHD",
  "title" : "PHD: Pertuzumab + Trastuzumab + Docetaxel — Metastatic HER2+ Breast Cancer",
  "type" : {
    "coding" : [
      {
        "system" : "http://terminology.hl7.org/CodeSystem/plan-definition-type",
        "code" : "order-set",
        "display" : "Order Set"
      }
    ]
  },
  "status" : "active",
  "experimental" : true,
  "subjectCodeableConcept" : {
    "coding" : [
      {
        "system" : "http://snomed.info/sct",
        "code" : "254837009",
        "display" : "Malignant neoplasm of breast"
      }
    ]
  },
  "date" : "2026-09-08T18:17:28-04:00",
  "publisher" : "HL7 International / Clinical Interoperability Council",
  "contact" : [
    {
      "name" : "HL7 International / Clinical Interoperability Council",
      "telecom" : [
        {
          "system" : "url",
          "value" : "http://www.hl7.org/Special/committees/cic"
        },
        {
          "system" : "email",
          "value" : "ciclist@lists.HL7.org"
        }
      ]
    }
  ],
  "description" : "PHD regimen every 21 days for HER2+ metastatic breast cancer. Standard of care per CLEOPATRA trial.",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US",
          "display" : "United States of America"
        }
      ]
    }
  ],
  "action" : [
    {
      "id" : "pertuzumab-phd",
      "title" : "Pertuzumab 840 mg IV (cycle 1), then 420 mg IV q21d",
      "timingTiming" : {
        "repeat" : {
          "period" : 21,
          "periodUnit" : "d"
        }
      }
    },
    {
      "id" : "trastuzumab-phd",
      "title" : "Trastuzumab 8 mg/kg IV (cycle 1), then 6 mg/kg IV q21d",
      "timingTiming" : {
        "repeat" : {
          "period" : 21,
          "periodUnit" : "d"
        }
      }
    },
    {
      "id" : "docetaxel-phd",
      "title" : "Docetaxel 75 mg/m² IV — Day 1 of each 21-day cycle",
      "timingTiming" : {
        "repeat" : {
          "period" : 21,
          "periodUnit" : "d"
        }
      }
    }
  ]
}